The DRCR Retina Network is planning an exciting new Phase III clinical trial to prevent visual acuity loss due to radiation retinopathy (RR). Eligible participants will be randomized to receive either repeated injections of anti-VEGF, long-active steroid, or observation following treatment of choroidal melanoma with I-125 plaque brachytherapy.
Any interested physicians or clinical sites should contact [email protected] to learn more about joining the Network.